RE:Very important read for CGN shareholdersNot only will Eisai & Biogen need CGN's digital diagnostic tool CognICA to monitor regularly existing Alzheimer's patients taking their new Alzheimer's drug Lecanemab, but they will also need CognICA to test the general population of over 55 years old on a yearly basis for early signs of Alzheimer's to find those patients who would benefit from taking Lecanemab.<br /> <br /> Roche invited CGN to demonstrate CognICA to their Alzheimer's team for this very purpose. Unfortunately, Roche's Alzheimer's drug failed in clinical trials, but not Eisai's & Biogen's drug Lecanemab, which received fast track FDA approval on Jan 6, 2023. Eisai & Biogen have also submitted Lecanemab for approval in China, Europe & Japan.<br /> <br /> CGN is the only company in the world with a digital diagnostic test, CognICA, capable of detecting early signs of Alzheimer's at low cost, across whole populations, efficiently & effectively. CognICA has been approved by the FDA in the U.S. as well as in Europe and the UAE so far.<br /> <br /> The global sky is literally the limit for CGN & CognICA!